News & Events

Investors

E-mail Alerts

Jan 6, 2021

Viking Therapeutics Announces Senior Management Team Appointments

Greg Zante Promoted to Chief Financial Officer and Marianne Mancini Promoted to Chief Operating Officer

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Jan 5, 2021

Viking Therapeutics to Present at H.C. Wainwright BioConnect 2021 Conference

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Nov 10, 2020

Viking Therapeutics to Present at Stifel Healthcare Conference 2020

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Oct 28, 2020

Viking Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced...
Oct 21, 2020

Viking Therapeutics to Report Financial Results for Third Quarter 2020 on October 28, 2020

Conference Call Scheduled for Wednesday, October 28 at 4:30 p.m. Eastern Time

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced today...